Diabetes Research and Clinical Practice
Volume 68, Issue 2 , Pages 117-125 , May 2005

Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density

  • Kiyoshi Suzuki

      Affiliations

    • Third Department of Internal Medicine, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo 181-8611, Japan
    • Department of Internal Medicine, Shimada Municipal Hospital, Shimada, Shizuoka 427-8502, Japan
    • ,
  • Takeshi Kurose

      Affiliations

    • Department of Internal Medicine, Shimada Municipal Hospital, Shimada, Shizuoka 427-8502, Japan
    • ,
  • Makoto Takizawa

      Affiliations

    • Third Department of Internal Medicine, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo 181-8611, Japan
    • ,
  • Masahiro Maruyama

      Affiliations

    • Third Department of Internal Medicine, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo 181-8611, Japan
    • ,
  • Kenji Ushikawa

      Affiliations

    • Third Department of Internal Medicine, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo 181-8611, Japan
    • ,
  • Munetsugu Kikuyama

      Affiliations

    • Department of Internal Medicine, Shimada Municipal Hospital, Shimada, Shizuoka 427-8502, Japan
    • ,
  • Chieko Sugimoto

      Affiliations

    • Department of Internal Medicine, Shimada Municipal Hospital, Shimada, Shizuoka 427-8502, Japan
    • ,
  • Yutaka Seino

      Affiliations

    • Department of Metabolism and Clinical Nutrition, Kyoto University School of Medicine, Sakyo-ku, Kyoto 606-8507, Japan
    • ,
  • Shinya Nagamatsu

      Affiliations

    • Second Department of Biochemistry, Kyorin University School of Medicine, Mitaka, Tokyo 181-8611, Japan
    • ,
  • Hitoshi Ishida

      Affiliations

    • Third Department of Internal Medicine, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo 181-8611, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 422 47 5511x5822; fax: +81 422 76 6451.

Received 9 December 2003 ,Revised 28 July 2004 ,Accepted 19 August 2004.

References 

  1. Me Levin J, Vincenza C, Boisseau VC, Avioli LV. Effects of diabetes mellitus on bone mass in juvenile and adult-onset diabetes. N. Eng. J. Med. 1976;294:241–245
  2. McNair P, Madsbad S, Christiansen C, Faber OK, Transbøl I, Binder C. Osteopenia in insulin treated diabetes mellitus. Its relation to age at onset, sex and duration of disease. Diabetologia. 1978;15:87–90
  3. Ishida H, Seino Y, Matsukura S, et al. Diabetic osteopenia and circulating levels of vitamin D metabolites in type 2 (noninsulin-dependent) diabetes. Metabolism. 1985;34:797–801
  4. Seino Y, Ishida H. Diabetic osteopenia: pathophysiology and clinical aspects. Diabetes Metab. Rev. 1995;11:21–35
  5. Okazaki R, Totsuka Y, Hamano K, et al. Metabolic improvement of poorly controlled noninsulin-dependent diabetes mellitus decreases bone turnover. J. Clin. Endocrinol. Metab. 1997;82:2915–2970
  6. Suzuki K, Sugimoto C, Takizawa M, et al. Correlation between bone mineral density and circulating bone metabolic markers in diabetic patients. Diabetes Res. Clin. Pract. 2000;48:185–191
  7. Suzuki K, Taguchi Y, Ishida H, Seino Y. The evidence for uncoupling between bone formation and resorption in NIDDM patients. Diabetologia. 1997;40(Suppl. 1):A581
  8. Okazaki R, Miura M, Toriumi M, et al. Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus. Endocr. J. 1999;46:795–801
  9. Donde M, Fledelius C, Qvist P, Christiansen C. Coated-tube radioimmunoassay for C-telopeptides of type I collagen to assess bone resorption. Clin. Chem. 1996;42:1639–1644
  10. Unbelhart D, Schlemmer A, Johansen JS, Gineyts E, Christiansen C, Delmas P. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J. Clin. Endocrinol. Metab. 1991;72:367–373
  11. Da Hanson MA, Weis AM, Bollen SL, Maslan FR, Singer DR. Eyre Specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptide in urine. J. Bone Miner. Res. 1992;7:1251–1258
  12. Anderson DM, Marakovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendric-cell function. Nature. 1997;390:175–179
  13. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165–176
  14. Tsuda E, Goto M, Mochizuki S, et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem. Biophys. Res. Commun. 1997;234:137–142
  15. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J. Clin. Endocrinol. Metab. 2001;86:631–637
  16. Suzuki K, Ishida H, Sugimoto C, et al. The urinary concentration of sialic acid is increased in non-insulin-dependent diabetic patients with microangipathy: a possible useful marker for diabetic microangiopathy. Diabetic Med. 1995;12:1092–1096
  17. Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins. Science. 1999;286:1946–1949
  18. Ishida H, Suzuki K, Someya Y, et al. Possible compensatory role of parathyroid hormone-related peptide on maintenance of calcium homeostasis in patients with non-insulin dependent diabetes mellitus. Acta Endocrinol. (Copenhagen). 1993;129:519–524
  19. Nakashima K, Hattori Y, Yamazaki K, et al. Immediate elimination of labile HbA1c with allosteric effectors of hemoglobin. Diabetes. 1990;39:17–21
  20. Takai K, Nanaka K, Ichihara K, et al. Food constituents as a cause of variation of C-peptide excretion in the urine. Endocrinol. Jpn. 1984;31:291–299
  21. Hosoda K, Eguchi H, Nakamoto T, et al. Sandwich immunoassay for intact osteocalcin. Clin. Chem. 1992;38:2233–2238
  22. Suzuki K, Ishida H, Takeshita T, et al. Circulating levels of tartrate-resistant acid phosphatase in rat models of non-insulin-dependent diabetes mellitus. J. Diabetes Comp. 1998;12:176–180
  23. Fraser WD, Durham BH, Berry JL, Mawer EB. Measurement of plasma 1, 25 dihydroxyvitamin D using a novel immunoextraction technique and immunoassay with iodine labeled vitamin D tracer. Ann. Clin. Biochem. 1997;34:632–637
  24. Van Daele PLA, Stolk RP, Burger H, et al. Bone density in non-insulin-dependent diabetes mellitus. Ann. Intern. Med. 1995;122:409–414
  25. Krakauer JC, Mckenna MJ, Buderer NF, Rao DS, Whitehouse FW, Parfitt AM. Bone loss and bone turnover in diabetes. Diabetes. 1995;44:775–782
  26. Hough S, Avioli LV, Bergfell MA, Fallon MD, Slatopolsky E, Teitelbaum SL. Correction of abnormal bone and mineral metabolism in chronic streptozotocin-induced diabetes mellitus in the rat by insulin therapy. Endocrinology. 1981;108:2228–2234
  27. Ishida H, Seino Y, Taminato T, et al. Circulating levels and bone contents of bone γ-carboxyglutamic acid-containing protein are decreased in streptozotocin-induced diabetic osteopenia. Diabetes. 1988;37:702–706
  28. Takeshita N, Ishida H, Yamamoto T, et al. Circulating levels of and bone contents of bone γ-carboxyglutamic acid-containing protein in rat models of noninsulin-dependent diabetes mellitus. Acta Endocrinol. (Copenhagen). 1993;128:69–73
  29. Verhaegue J, Suiker AM, Einhorn TA, et al. Brittle bones in spontaneously diabetic female rats cannot be predicted by bone mineral measurements: Studies in diabetic and ovariectomized rats. J. Bone Miner. Res. 1994;9:1657–1667
  30. Piekorn B, Kann P, Forst T, Andreas J, Ptűtzner A, Beyer J. Bone mineral density and bone metabolism in diabetes mellitus. Horm. Metab. Res. 1997;29:204–219
  31. Fledelius C, Johnsen AH, Cloos P, Bonde M, Qvist P. Characterization of urinary degradation products derived from type I collagen. J. Biol. Chem. 1997;272:9755–9763
  32. Colwell A, Russell RGG, Eastell R. Factors affecting the assay of urinary 3-hydroxypyridinium crosslinks of collagen as markers of bone resorption. Eur. J. Clin. Invest. 1993;23:341–349
  33. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. U.S.A. 1998;95:3597–3602
  34. Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology. 1998;139:1329–1337
  35. Kazama JJ, Shigematsu T, Yano K, et al. Increased circulting levels of osteoclastgenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am. J. Kidney Dis. 2002;39:525–532
  36. Simonet WS, Lacey DL, Dunsta CR, et al. Osteoprotegrin: a nobel secreted protein involved in the regulation of bone density. Cell. 1997;89:309–319
  37. Schwartz AV, Sellmeyer DE, Ensrud KE, et al. Older women with diabetes have an increased risk of fracture; a prospective study. J. Clin. Endocrinol. Metab. 2001;86:32–38

PII: S0168-8227(04)00281-5

doi: 10.1016/j.diabres.2004.08.006

Diabetes Research and Clinical Practice
Volume 68, Issue 2 , Pages 117-125 , May 2005

Article Tools

* Image Usage & Resolution